[
    {
        "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "aho1PoHFhoJFojcpMyQKZGb7HKyl149YlzPcaYrfwnZ81Sun1SF3GpfuHs5Jbdz5PsbPnsoShdoD7MDUAz3IHjncWvIhWhezpBs5DKHKs4M7Xbsckl0AjhHeTFOtdDLCA4eXJ3b96Ey6ZG7X4xbTyLkxhy6pSILf7RrHvn7S7iM="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-08-23T13:00:18.351+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_2349",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_2349"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB01255"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "\"Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncratic reaction to sympathomimetic amines, glaucoma Agitated states Patients with a history of drug abuse During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result) [   See Drug Interactions (7.3)   Advanced arteriosclerosis (   4 Symptomatic cardiovascular disease (   4 Moderate to severe hypertension (   4 Hyperthyroidism (   4 Known hypersensitivity or idiosyncrasy to sympathomimetic amines (   4 Glaucoma (   4 Agitated states (   4 History of drug abuse (   4 During or within 14 days following the administration of monoamine oxidase inhibitors (MAOI) (   4   7.3\""
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://schema.org/MedicalContraindication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB01255",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    }
]